Annovis Bio Inc. (ANVS): Price and Financial Metrics


Annovis Bio Inc. (ANVS): $24.99

-3.87 (-13.41%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ANVS Stock Price Chart Interactive Chart >

Price chart for ANVS

ANVS Price/Volume Stats

Current price $24.99 52-week high $47.99
Prev. close $28.86 52-week low $3.36
Day low $24.40 Volume 188,100
Day high $29.90 Avg. volume 254,772
50-day MA $26.83 Dividend yield N/A
200-day MA $12.96 Market Cap 173.61M

Annovis Bio Inc. (ANVS) Company Bio


Annovis Bio, Inc. develops drugs for Alzheimer's and Parkinson's diseases and other neurodegenerative disorders. It offers posiphen compound for mild cognitive impairment and early stage Alzheimer's disease and bisnorcymserine compound that inhibits amyloid formation and prevents the progression of the Alzheimer's disease. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.


ANVS Latest News Stream


Event/Time News Detail
Loading, please wait...

ANVS Latest Social Stream


Loading social stream, please wait...

View Full ANVS Social Stream

Latest ANVS News From Around the Web

Below are the latest news stories about Annovis Bio Inc that investors may wish to consider to help them evaluate ANVS as an investment opportunity.

Annovis Bio to Participate at the Benzinga Global Small Cap Conference and Present to Investors on May 13, 2021

Berwyn, Pennsylvania--(Newsfile Corp. - May 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that management will participate at the Benzinga Global Small Cap Conference taking place online May 13-14, 2021.Annovis Bio CEO Maria Maccecchini, Ph.D. will deliver a corporate presentation at 3:10 p.m. ET on May 13, 2021. Investors can request a one-on-one meeting with ...

Yahoo | May 11, 2021

Annovis Bio to Ring Closing Bell at the New York Stock Exchange

Berwyn, Pennsylvania--(Newsfile Corp. - May 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, is pleased to announce that its CEO Maria Maccecchini, Ph.D. will ring The Closing Bell at the New York Stock Exchange (NYSE) today, May 10, to celebrate the recent reporting of positive interim data from its ongoing Phase 2a trial in AD and PD."We ...

Yahoo | May 10, 2021

Annovis Bio to Study Potential of ANVS401 to Normalize Brain Development in Down Syndrome

Collaborative mice study with UC San Diego to study brain development from embryo to old age Berwyn, Pennsylvania--(Newsfile Corp. - April 29, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced a new research collaboration with Professor William Mobley and Dr. Xuqiao Chen at the University of California San Diego designed to study the ability of the Company's ...

Yahoo | April 29, 2021

Do Insiders Own Lots Of Shares In Annovis Bio, Inc. (NYSEMKT:ANVS)?

The big shareholder groups in Annovis Bio, Inc. ( NYSEMKT:ANVS ) have power over the company. Generally speaking, as a...

Yahoo | April 24, 2021

Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients

Berwyn, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results of an interim analysis from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of PD and AD. Patients' speed and coordination scores both improved following 25 days of ANVS401 treatment, with no serious adverse events.Dr. …

Yahoo Finance | March 16, 2021

Read More 'ANVS' Stories Here

ANVS Price Returns

1-mo -0.32%
3-mo 19.11%
6-mo 416.32%
1-year 592.24%
3-year N/A
5-year N/A
YTD 231.43%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7738 seconds.